Evidence map›Paper›PMID 34837432›Full record

ArticleHuman mutation2022

Recommendations by the ClinGen Rett/Angelman-like expert panel for gene-specific variant interpretation methods.

Dianalee McKnight, Lora Bean, Izabela Karbassi, Katelynn Beattie, Thierry Bienvenu, Hope Bonin, Ping Fang, John Chrisodoulou, Michael Friez, Maria Helgeson and 8 more

Abstract read
In one paragraph

Article in Human mutation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Rett syndrome: The Natural History Study journey.Annals of the Child Neurology Society · 2024
    Review
  8. Article
  9. Article
  10. Stem cell models of Angelman syndrome.Frontiers in cell and developmental biology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Dianalee McKnightInvitae, San Francisco, California, USA.ORCID 0000-0002-7462-6300
Lora BeanPerkin Elmer, Duluth, Georgia, USA.
Izabela KarbassiAthena Diagnostics, Worcester, Massachusetts, USA.
Katelynn BeattieGeneDx, Gaithersburg, Massachusetts, USA.
Thierry BienvenuInstitut de Psychiatrie et de Neurosciences de Paris (IPNP), Paris, France.ORCID 0000-0002-5953-2728
Hope BoninCentral Manchester University Hospital, Manchester, Greater Manchester, UK.
Ping FangBaylor College of Medicine, Houston, Texas, USA.
John ChrisodoulouMurdoch Childrens Research Institute and the University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0002-8431-0641
Michael FriezGreenwood Genetic Center, Greenwood, South Carolina, USA.
Maria HelgesonInvitae, San Francisco, California, USA.
Rahul KrishnarajUniversity of Sydney, Sydney, New South Wales, Australia.
Linyan MengBaylor College of Medicine, Houston, Texas, USA.ORCID 0000-0001-7474-9178
Lindsey MighionGeneDx, Gaithersburg, Massachusetts, USA.
Jeffrey NeulVanderbilt Kennedy Center, Nashville, Tennessee, USA.
Alan PercyUniversity of Alabama at Birmingham, Birmingham, Alabama, USA.
Simon RamsdenCentral Manchester University Hospital, Manchester, Greater Manchester, UK.
Huda ZoghbiBaylor College of Medicine, Houston, Texas, USA.
Soma DasUniversity of Chicago, Chicago, Illinois, USA.

Funding

Resource ProjectU41HG006834 · NHGRI · BRIGHAM AND WOMEN'S HOSPITAL · PI REHM, HEIDI L · 2013 to 2020
$26.9M
ClinGen AI Data Delivery SupplementU24HG006834 · NHGRI · BROAD INSTITUTE, INC. · PI Marina DiStefano, CHRISTA LESE MARTIN · 2021 to 2026
$26.7M
Overall: Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center at VanderbiltP50HD103537 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jeffrey L Neul · 2020 to 2026
$10.3M
NHGRI NIH HHS U24 HG006834NHGRI NIH HHS U41 HG006834NICHD NIH HHS P50 HD103537
6 · The paper itself

Abstract

The genes MECP2, CDKL5, FOXG1, UBE3A, SLC9A6, and TCF4 present unique challenges for current ACMG/AMP variant interpretation guidelines. To address those challenges, the Rett and Angelman-like Disorders Variant Curation Expert Panel (Rett/AS VCEP) drafted gene-specific modifications. A pilot study was conducted to test the clarity and accuracy of using the customized variant interpretation criteria. Multiple curators obtained the same interpretation for 78 out of the 87 variants (~90%), indicating appropriate usage of the modified guidelines the majority of times by all the curators. The classification of 13 variants changed using these criteria specifications compared to when the variants were originally curated and as present in ClinVar. Many of these changes were due to internal data shared from laboratory members however some changes were because of changes in strength of criteria. There were no two-step classification changes and only 1 clinically relevant change (Likely pathogenic to VUS). The Rett/AS VCEP hopes that these gene-specific variant curation rules and the assertions provided help clinicians, clinical laboratories, and others interpret variants in these genes but also other fully penetrant, early-onset genes associated with rare disorders.

Indexed as

Genetic TestingGenome, HumanGenetic VariationHumansPilot ProjectsAngelman syndromeChristianson syndromeguidelinesPitt-Hopkins syndromeRett syndromevariant interpretation

Identifiers

PMID34837432
PMCPMC9135956

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.